Advertisement
New Zealand markets closed

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NZD/USD

    0.5932
    -0.0017 (-0.29%)
     

  • NZD/EUR

    0.5554
    +0.0014 (+0.25%)
     

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • OIL

    83.50
    -0.07 (-0.08%)
     

  • GOLD

    2,345.70
    +3.20 (+0.14%)
     

  • NASDAQ

    17,695.40
    +264.89 (+1.52%)
     

  • FTSE

    8,139.52
    +60.66 (+0.75%)
     

  • Dow Jones

    38,152.35
    +66.55 (+0.17%)
     

  • DAX

    18,162.68
    +245.40 (+1.37%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • NZD/JPY

    93.3170
    +0.8210 (+0.89%)
     

In Vitro Diagnostics Market in China 2021-2026, Featuring Abbott Laboratories, Arkray, Biomerieux, Hologic and Thermo Fisher Scientific

Research and Markets
·3-min read

Dublin, Jan. 24, 2022 (GLOBE NEWSWIRE) -- The "In Vitro Diagnostics (IVD) Market in China, 2021" report has been added to ResearchAndMarkets.com's offering.

As an in vitro diagnostics (IVD) market, China trails only the populous, developed economy markets of the United States, western European countries, and Japan. The country and its healthcare system are confronted by challenges shared by less developed countries, but also burdens common among developed middle-income and affluent countries such as diabetes, cardiovascular disease, and diseases of aging.

China as an IVD market opportunity is defined by its standing next to other populous countries with demonstrated economic promise for over the past decade - Brazil, Russia and India (collectively with China referred to as the important, rapidly growing "BRIC" nations).

The report, In Vitro Diagnostic (IVD) Markets in China, 2021, is designed to provide the reader with an overview of the Chinese laboratory market and its influences. The focus is on the IVD discipline including reagents, consumables, calibrators and controls of the following sub-segments:

ADVERTISEMENT

  • Clinical Chemistry: routine lab testing; substrates, enzymes, homogeneous immunoassays, proteins, ISE (non-POC), HBA1c (non-POC), includes urinalysis and blood chemistry testing.

  • Immunoassays: hormones and thyroid function, tumor markers, allergy, anemia, neonatal tests, prenatal tests, interleukins, PCT, toxicology and common infectious diseases (HIV, hepatitis, influenza)

  • Microbiology and Molecular Testing: manual and automated tests, culture media (to be prepared or ready to use), latex tests, transport media, blood culture, sensitivity discs, Gram and other stains, MTB culture, Mycoplasma, Ureaplasma, nucleic acid testing.

  • Point-of-Care Testing: all POC tests for cardiology, toxicology, coagulation, diabetes, infectious diseases, including POC and non-POC blood gas and electrolytes, and glucose self-monitoring tests.

  • Histology/Cytology: PAP, HE, IHC, ISH, FISH, primary and secondary antibodies.

Included in the report are trends influencing the industry and country-level data including the incidence of disease, life expectancy, population demographics, economic status, healthcare utilization and other market influences.

All market data pertains to the IVD market in China at the manufacturers' level. Market data is presented for the 2021 year with forecast data provided for 2026. Compound annual growth rates (CAGRs) are provided for the 2021-2026 period.


Key Topics Covered:

Chapter one: Executive Summary

  • Scope and methodology

  • Major findings of the report

  • IVD market in china

Chapter two: China in context

  • Overview

  • Population trends

  • Disease demographics

  • Infectious disease threats

  • Chinese economy

Chapter three: Clinical laboratory structure in china

  • Clinical laboratory tests

  • Chinese healthcare reform and hospital infrastructure

  • China regulation and medical device policy challenges

Chapter four: IVD markets in china

  • Market introduction and summary

  • Clinical chemistry

  • Point-of-care (POC) testing

  • Immunoassays

  • Molecular assays

  • Hematology

  • Coagulation

  • Microbiology

  • Tests used in blood banking

  • Histology and cytology

  • Prenatal and genetic test services

Chapter five: Company activity in china

  • China IVD market participant overview

Companies Mentioned

  • Abbott Laboratories

  • Arkray

  • Becton, Dickinson & Co.

  • Biomerieux, Inc.

  • Bio-Rad Laboratories, Inc.

  • Danaher Corp.

  • Hologic, Inc.

  • Horiba Medical

  • Instrumentation Laboratory

  • Luminex Corporation

  • Mindray Medical International, Ltd.

  • Myriad Genetics

  • Ortho Clinical Diagnostics

  • Perkinelmer

  • Qiagen N.V.

  • Roche

  • Siemens Healthineers

  • Sysmex Corp.

  • Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/r/1rmn9q

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900